ClinicalTrials.gg
TerminatedNCT07086222COVID-19Updated Oct 23, 2026

Efficacy and Safety of NVX-CoV2705

A Phase 4 interventional study of NVX-CoV2705 and Placebo in COVID-19 and Sars-CoV-2 Infection, sponsored by Novavax. Terminated at 99 sites in United States. Open to participants aged 50 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Novavax · Phase 4, Interventional, and Prevention

Why this study was terminated
The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaningful vaccine efficacy assessment. The decision was made in consultation with FDA/CBER and was unrelated to safety concerns.
Updated Oct 23, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6,500
Allocation
Randomized
Ages
50 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in COVID-19 by Novavax — none open to participants now, none under way, none of them phase 3. COVID-19 · Novavax.

Enrollment
4th of 21
6,500 · median 911
Started
2025
with 1 other
Phase 4
2 of 21
none open now
Registered
21st of 21
by date

Among the 21 studies in COVID-19 by Novavax, this one is the 4th largest by enrollment, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 21st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 21 studies in COVID-19 by Novavax is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 50 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in COVID-19 by Novavax as a file.
02

Study summary

This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.

Read the detailed description

This is a Phase 4, multicenter, randomized, double-blind, placebo-controlled, post-marketing study to evaluate the efficacy and safety of a single dose of an Omicron JN.1 subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine (SARS-CoV-2 rS) adjuvanted with Matrix-M (NVX-CoV2705) in adults 50 to \< 65 years of age who are not considered to be at high risk of severe coronavirus disease 2019 (COVID-19). This study will be conducted in the United States (US).

Approximately 6,500 participants will be randomized in a 1:1 ratio via block randomization to receive a single intramuscular (IM) injection of NVX-CoV2705 or placebo (normal saline) on Day 0 and remain on study for efficacy and safety data collection through Day 180/end of study (EoS).

03

Conditions studied

  • COVID-19
  • Sars-CoV-2 Infection

Browse trials for

Keywords

  • COVID-19
04

Who can participate

Ages eligible
50 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be included in this study, each individual must satisfy all of the following criteria:

    1. Adults 50 to \< 65 years of age at time of study vaccination (Day 0) who are not considered to be at high risk of severe COVID-19.
    2. Participants unvaccinated to SARS-CoV-2 or participants previously vaccinated with a COVID-19 vaccine ≥ 90 days prior to study vaccination.
    3. Participant or legally acceptable representative is willing and able to give prior to study enrollment and to comply with study procedures.
    4. Female participants of (defined as any participant who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or [defined as amenorrhea ≥ 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through 90 days after vaccination OR agree to consistently use a medically acceptable method of listed below from ≥ 28 days prior to enrollment and through 90 days after vaccination.

      1. Condoms (male or female) with spermicide (if acceptable in country)
      2. Diaphragm with spermicide
      3. Cervical cap with spermicide
      4. Intrauterine device
      5. Oral or patch contraceptives
      6. Norplant®, Depo-Provera®, or other in country regulatory approved contraceptive method that is designed to protect against pregnancy
      7. Abstinence, as a form of contraception, is acceptable if in line with the participant's lifestyle NOTE: Periodic abstinence (eg, calendar, ovulation, sympto-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    5. Agrees not to participate in any research involving receipt of products (drug/biologic/device), including other SARS-CoV-2 prevention or treatment trials, for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • If an individual meets any of the following criteria, he or she is ineligible for this study:

    1. Is considered to be at high risk of severe COVID-19 due to underlying medical conditions or risk factors that demonstrated a conclusive increase in risk for at least one severe COVID-19 outcome, as described by the Centers for Disease Control and Prevention (CDC) .
    2. Unstable acute illness at the time of vaccination.
    3. Participation at the time of study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
    4. Current participation in any other COVID-19 prevention clinical trial.
    5. Known history of COVID-19 infection within 90 days of study vaccination.
    6. Any known history of allergies to products contained in the product in the participant's lifetime.
    7. Any known history of anaphylaxis to any prior vaccine in the participant's lifetime.
    8. Known history of myocarditis or pericarditis in the participant's lifetime.
    9. Chronic administration (defined as > 14 continuous days) of , systemic , or other immune-modifying drugs within 90 days prior to study vaccination (Day 0).

      NOTE: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, or intranasal glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are permitted.

    10. Received immunoglobulin or blood-derived products within 90 days prior to study vaccination (Day 0).
    11. Participants who are pregnant, or who plan to become pregnant within 90 days following study vaccination.
    12. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
    13. Study team member or immediate family member of any study team member (inclusive of Sponsor, clinical research organization [CRO], and study site personnel involved in the conduct or planning of the study).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
6,500 participants (actual)

Study arms

  • Experimental
    NVX-CoV2705

    a single intramuscular (IM) injection of NVX-CoV2705 on Day 0

    Biological: NVX-CoV2705

  • Placebo comparator
    Placebo

    a single intramuscular (IM) injection of placebo (normal saline) on Day 0

    Biological: Placebo

Interventions

  • BiologicalNVX-CoV2705

    NVX-CoV2705 vaccine in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant

    Also known as: Omicron JN.1 subvariant SARS-CoV-2 rS vaccine adjuvanted with Matrix-M

  • BiologicalPlacebo

    Placebo (normal saline) in a 0.5 mL injection volume.

06

What researchers measure

Primary outcomes

  1. First episode of PCR-positive symptomatic COVID 19

    First episode of PCR-positive symptomatic COVID 19 from Day 0 (post vaccination) through Day 180/EoS

    Time frame: Day 0 to Day 180

Secondary outcomes

  1. First episode of PCR-positive symptomatic COVID 19

    First episode of PCR-positive symptomatic COVID 19 after completion of the injection through Day 180/EoS

    Time frame: Day 42 to Day 180

  2. Participants with Medically attended adverse events (MAAEs), Serious adverse event (SAEs) and Adverse event of special interest (AESIs)

    Number of participants reported MAAEs attributable to study vaccine, SAEs, or AESIs through Day 180/EoS.

    Time frame: Day 180

07

Study locations

99 sites
  • North Alabama Research Center
    Athens, Alabama 35611, United States
  • TrialMed - Birmingham
    Birmingham, Alabama 35211, United States
  • Hawthorne Health - Gadsden
    Gadsden, Alabama 35901, United States
  • TrialdMed - Huntsville
    Huntsville, Alabama 35802, United States
  • AMR Mobile
    Mobile, Alabama 36608, United States
  • Headlands Research Scottsdale
    Scottsdale, Arizona 85260, United States
  • Orange Grove Family Practice
    Tucson, Arizona 85741, United States
  • 310 Clinical Research
    Inglewood, California 90301, United States
  • Velocity Clinical Research - San Diego
    La Mesa, California 91942, United States
  • Profound Research LLC at Seaside Medical Group
    Oceanside, California 92058, United States
  • California Research Foundation
    San Diego, California 92123, United States
  • Bayview Research Group, LLC
    Valley Village, California 91607, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Alliance Clinical - West Hills
    West Hills, California 91303, United States
  • Lynn Institute of Denver
    Aurora, Colorado 80012, United States
  • Paradigm Clinical Research Centers, LLC
    Wheat Ridge, Colorado 80033, United States
  • Clinical Research Consulting, LLC
    Milford, Connecticut 06460, United States
  • SIMED Health, LLC / SIMED Research
    Gainesville, Florida 32607, United States
  • Indago Research and Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Health Awareness, LLC
    Jupiter, Florida 33458, United States
  • TrialMed - Melbourne
    Melbourne, Florida 32934, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Research Institute Of South Florida, Inc.
    Miami, Florida 33173, United States
  • MOORE Clinical Research
    Tampa, Florida 33609, United States
  • TrialMed - The Villages
    The Villages, Florida 32162, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • CenExel Atlanta GA
    Atlanta, Georgia 30331, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Velocity Clinical Research, Boise
    Meridian, Idaho 83642, United States
  • Accellacare of Duly
    Lombard, Illinois 60148, United States
  • Accellacare Duly Health and Care
    Oak Lawn, Illinois 60453, United States
  • TrialMed
    Evansville, Indiana 47714, United States
  • Velocity Clinical Research, Valparaiso
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research, Sioux City
    Sioux City, Iowa 51106, United States
  • Integrated Clinical Trial Services
    West Des Moines, Iowa 50265, United States
  • DelRicht Research @ Concierge and Direct Primary Care
    Overland Park, Kansas 66209, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • Alliance for Multispecialty Research, L.L.C.
    Lexington, Kentucky 40509, United States
  • DelRicht Research @ Touro Medical Center
    New Orleans, Louisiana 70115, United States
  • DelRicht Research @ Matthew Mintz Clinic
    Rockville, Maryland 20852, United States
  • Profound Research LLC at Millennium Affiliated Physicians
    Farmington Hills, Michigan 48334, United States
  • Great Lakes Research Institute, LLC
    Southfield, Michigan 48075, United States
  • Clinical Research Institute, Inc
    Minneapolis, Minnesota 55402, United States
  • DelRicht Research at Gulfport Memorial
    Gulfport, Mississippi 39503, United States
  • AMR Kansas City
    Kansas City, Missouri 64114, United States
  • Sundance Clinical Research
    St Louis, Missouri 63141, United States
  • Boeson Research
    Missoula, Montana 59804, United States
  • Velocity Clinical Research, Lincoln
    Lincoln, Nebraska 68510, United States
  • Velocity Clinical Research
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
  • TrialMed - Las Vegas
    Las Vegas, Nevada 89113, United States
  • AMR Clinical - Las Vegas
    Las Vegas, Nevada 89119, United States
  • Hawthorne Health - Lindenwold
    Lindenwold, New Jersey 08021, United States
  • IMA Clinical Research - Albuquerque
    Albuquerque, New Mexico 87109, United States
  • Velocity Clinical Research - Binghampton
    Binghamton, New York 13905, United States
  • Rochester Clinical Research
    Buffalo, New York 14217, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Hawthorne Health - Staten
    Staten Island, New York 10309, United States
  • Hawthorne Health - Concord
    Concord, North Carolina 28025, United States
  • Monroe Pharmaceutical Research
    Monroe, North Carolina 28112, United States
  • Accellacare of Rocky Mount
    Rocky Mount, North Carolina 27804, United States
  • Accellacare Research of Salisbury
    Salisbury, North Carolina 28144, United States
  • Accellacare Research of Winston Salem
    Winston-Salem, North Carolina 27103, United States
  • DSI Research - Northridge
    Dayton, Ohio 45414, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73072, United States
  • Lynn Health Institute - OKC
    Oklahoma City, Oklahoma 73112, United States
  • DelRicht Research @ Grassroots Healthcare
    Tulsa, Oklahoma 74133, United States
  • Velocity Clinical Research, Medford
    Medford, Oregon 97504, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Hawthorne Health - Horsham
    Horsham, Pennsylvania 19044, United States
  • Suburban Research Associates - West Chester Office
    West Chester, Pennsylvania 19380, United States
  • K2 Medical Research - East Providence
    East Providence, Rhode Island 02914, United States
  • DelRicht Research @ Newton Family Medicine
    Charleston, South Carolina 29407, United States
  • Piedmont Research Partners
    Fort Mill, South Carolina 29707, United States
  • Trial Management Associates (TMA ) Headlands LLC
    Myrtle Beach, South Carolina 29572, United States
  • Accellacare of Bristol
    Bristol, Tennessee 37620, United States
  • WR Clinsearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Summit-Halls Family Practice
    Knoxville, Tennessee 37938, United States
  • Hawthorne Health - Lebanon
    Lebanon, Tennessee 37087, United States
  • International Clinical Research - Tennessee
    Murfreesboro, Tennessee 37130, United States
  • Avacare
    Austin, Texas 78705, United States
  • TrialMed - Austin
    Austin, Texas 78744, United States
  • Howland Allergy & Asthma PLLC dba Orion Clinical Research
    Austin, Texas 78759, United States
  • Zenos Clinical Research
    Dallas, Texas 75230, United States
  • Avacare
    Fort Worth, Texas 76135, United States
  • SMS Clinical Research LLC
    Mesquite, Texas 75149, United States
  • ACRC Trials
    Plano, Texas 75093, United States
  • Research Your Health
    Plano, Texas 75093, United States
  • Flourish San Antonio - Clinical
    San Antonio, Texas 78229, United States
  • TrialMed - San Antonio
    San Antonio, Texas 78229, United States
  • Sugar Lakes Family Practice, P.A.
    Sugar Land, Texas 77479, United States
  • Boeson Research - Utah
    Provo, Utah 84604, United States
  • University of Utah
    Salt Lake City, Utah 84108, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • Charlottesville Medical Research Center, LLC
    Charlottesville, Virginia 22911, United States
  • Health Research of Hampton Roads, Inc
    Newport News, Virginia 23606, United States
  • Velocity Clinical Research, Seattle
    Seattle, Washington 98105, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2025 to primary completion in Oct 2026, 10 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Nov 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 25, 2025
StartActual
Nov 20, 2025
Primary completionActual
Oct 9, 2026was Nov 2026
CompletionActual
Oct 9, 2026was Nov 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaningful vaccine efficacy assessment. The decision was made in consultation with FDA/CBER and was unrelated to safety concerns.
changed Oct 23, 2026
Primary completion
Nov 18, 2026→Oct 9, 2026 (actual)
Oct 23, 2026
Study completion
Nov 18, 2026→Oct 9, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Terminated
    Why stopped The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaningful vaccine efficacy assessment. The decision was made in consultation with FDA/CBER and was unrelated to safety concerns.
    Primary completion Nov 18, 2026→Oct 9, 2026 (now actual)
    Study completion Nov 18, 2026→Oct 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07086222
Lead sponsor
Novavax
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Nov 20, 2025
Primary completion
Oct 9, 2026
Completion
Oct 9, 2026
Last update
Oct 23, 2026

Study contacts

Clinical Development
study director · Novavax, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion